Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
For the evaluation of patients who have had neoadjuvant chemotherapy (NAC) for breast cancer, abbreviated magnetic resonance imaging (MRI) offers comparable assessment to full MRI for gauging treatment response, according to research presented at the Society for Breast Imaging (SBI) conference.
For the multicenter retrospective study, researchers compared abbreviated MRI and full MRI in 237 patients with breast cancer who had pre- and posr-NAC breast MRI. According to the study, 92 patients in the cohort had a pathologic complete response (pCR).1
Here can see abbreviated MRI findings of partial treatment response for a 44-year-old woman with invasive ductal carcinoma. (Images courtesy of the Society for Breast Imaging.)
While emphasizing the need for further prospective research, the researchers found no statistically significant difference between abbreviated MRI and full MRI with respect to the mean area under the receiver operating characteristic curve (AUC) for predicting pCR to NAC (69.7 percent vs. 68.7 percent).1
“(The abbreviated MRI) protocol can be used in the post-NAC setting for predicting complete pathologic response,” wrote Iris Chen, M.D., a radiology resident at the University of California-Los Angeles (UCLA) Ronald Reagan Medical Center, and colleagues.
The study authors noted a 39.8 percent mean max dimension of residual breast cancer for abbreviated MRI in comparison to 38.2 percent for full MRI.
“(There was) no significant difference in assessing residual disease between abMRI and full MRI, and between abMRI and pathology,” maintained Chen and colleagues.1
Abbreviated MRI also provided an 80.1 percent accuracy rate for detecting lymphadenopathy, according to the researchers.1
(Editor’s note: For related content, see “Abbreviated Breast MRI and Dense Breasts: What Emerging Research Reveals,” “Breast MRI Quantification of Intra-Tumoral Heterogeneity May Help Predict Response to Neoadjuvant Chemotherapy” and “Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?”)
Reference
1. Chen I, Linden O, Sayre J, et al. Efficacy of abbreviated breast MRI for the evaluation of post-neoadjuvant chemotherapy breast cancer. Presented at the Society for Breast Imaging (SBI) conference, April 24-27, 2025, Colorado Springs, Colo. Available at: https://www.sbi-online.org/events/2025-sbi-breast-imaging-symposium . Accessed April 24, 2025.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
